GlioCART is a University of Basel spin-out developing the first CAR-T cell therapy for glioblastoma (GBM), an aggressive brain cancer,
GlioCART has raised $188K in total funding. The most recent round was Seed. The last funding was announced in November 2025.
GlioCART's investors include Venture Kick, University of Basel.
GlioCART is headquartered in Allschwil, Switzerland.
GlioCART is a University of Basel spin-out developing the first CAR-T cell therapy for glioblastoma (GBM), an aggressive brain cancer,
GlioCART is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GlioCART — Funding & Investors." VCBacked, November 17, 2025, https://www.vcbacked.co/company/gliocart. Accessed July 20, 2026.
VCBacked. (2025). GlioCART — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/gliocart
{{cite web |title=GlioCART — Funding & Investors |url=https://www.vcbacked.co/company/gliocart |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated